Product design
TEVIMBRA is a unique PD-1 inhibitor, optimally designed for robust T-cell activation, with potential for synergistic combination1-5
TEVIMBRA is designed to increase T-cell activation
TEVIMBRA features a unique Fc-silent region, which minimizes binding to FcγR on macrophages and can increase the concentration of activated T cells.2,3
See what makes TEVIMBRA different in this short video:
Clinical significance of preclinical data has not been established.
TEVIMBRA may work synergistically with zanidatamab, a dual HER2-targeting agent1,4
Zanidatamab is not a T-cell engager. It is a bispecific antibody with dual HER2-targeted binding properties.
Zanidatamab binding to HER2 can result in:
- internalization and HER2 reduction
- induction of ADCC, ADCP, and CDC
- targeted tumor cell death
.
An Expert in Oncology Explains TEVIMBRA's Mechanism of Action
Ronan J. Kelly, MD, MBA, discusses how TEVIMBRA is a unique PD-1 inhibitor.
Frequently Asked Questions
What is the product design of TEVIMBRA?
How does TEVIMBRA work with zanidatamab?
TEVIMBRA may work synergistically with zanidatamab, a dual HER2-targeting agent. Zanidatamab is not a T-cell engager. It is a bispecific antibody with dual HER2-targeted binding properties. Zanidatamab binding to HER2 can result in internalization and HER2 reduction, targeted tumor cell death, and induction of ADCC, ADCP, and CDC.1,4